# A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)

> **NCT01245816** · PHASE3 · WITHDRAWN · sponsor: **Cancer Prevention Pharmaceuticals, Inc.**

## Conditions studied

- Familial Adenomatous Polyposis

## Interventions

- **DRUG:** Eflornithine plus Sulindac
- **DRUG:** Eflornithine plus Placebo
- **DRUG:** Sulindac plus Placebo

## Key facts

- **NCT ID:** NCT01245816
- **Lead sponsor:** Cancer Prevention Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-03
- **Primary completion:** 2013-05
- **Final completion:** 2013-06
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2015-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01245816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01245816, "A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT01245816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*